Methods	Eight-week randomised, double-blind multicentre study.
Participants	Outpatients fulfilling DSM-III criteria for moderate to severe major depressive disorder, non psychotic, with a score of at least 18 on the first 17 items of the HDRS-17. Age range: 19-55 years old. Exclusion criteria: engaged in a shiftwork, independent sleep/wake disorders, significant concurrent general medical conditions, DSM-III criteria for psychoactive use disorder within 1 year prior to study, other major lifetime Axis I disorders (organic mental syndrome, bipolar, any psychotic, any eating, panic or obsessive-compulsive disorder), pregnancy, lactation, absence of contraception
Interventions	Fluoxetine: 61 participants. Nefazodone: 64 participants. Fluoxetine dose range: 20-40 mg/day. Nefazodone dose range: 200-500 mg/day.
Outcomes	Hamilton Rating Scale for Depression (HDRS-17) total score, IDS-C, IDS-SR, CGI Improvement Notes Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear